Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Correlation tests with (a) AP, Alkaline Phosphatase; (b) iFGF23, intact Fibroblast Growth Factor 23; (c) 25D, 25-hydroxyvitaminD.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation

Study design awaiting verification · PLoS ONE · 2017

Original publication title

Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation

Lida Tartaglione; Marzia Pasquali; Silverio Rotondi; Maria Luisa Muci; Cristiana Leonangeli; Alessio Farcomeni; Valeria Fassino; Sandro Mazzaferro

© 2017 Tartaglione et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Relationships of Sclerostin, a bone anti-anabolic protein, with biomarkers of mineral bone disorders in chronic kidney disease are still unsettled, in particular in kidney transplant (KTR). In 80 KTR patients (31F/49M, 54.7±10.3 years) we studied the relationships of serum Sclerostin with eGFR, Calcium, Phosphate, Alkaline Phosphatase (AP), intact Parathyroid hormone (iPTH), soluble alpha-Klotho (sKlotho), intact Fibroblast Growth Factor 23 (iFGF23), 25-hydroxyvitamin D(25D) and 1,25-dihydroxyvitamin D (1,25D). Thirty healthy subjects (35.0±12.4 years, eGFR 109.1±14.1 ml /min/1,73m2) served as control for Sclerostin, iFGF23 and sKlotho.

With a median eGFR of 46.3 mL/min/1.73m2 (IQR, 36.2 to 58.3) our KTR had median Sclerostin levels of 23.7 pmol/L (IQR: 20.8 to 32.8), not different from controls (26.6 pmol/L, IQR: 22.0 to 32.2; p = n.s). Sclerostin correlated negatively with AP (r =: .251; p = 0.023) and positively with iFGF23 (r = .227; p = 0.017) and 25D (r = .214; p = 0.025). Age-adjusted multiple regression analysis identified AP and 1,25D as negative and 25D and sKlotho as positive best predictors of Sclerostin.

No correlation was evident with eGFR. The negative correlation with AP confirms the direct anti-anabolic role of Sclerostin. The associations either negative or positive with iFGF23, sKlotho, and vitamin D metabolites suggest also a modulatory role in mineral homeostasis. In particular, the associations with iFGF23 (positive) and 1,25D (negative) underline the relevant inhibitory action of Sclerostin on vitamin D activation. In conclusion, Sclerostin levels in KTR are normal and influenced more by bone turnover than by eGFR. Its involvement with other hormones of mineral homeostasis (FGF23/Klotho and Vitamin D) is part of the sophisticated cross-talk between bone and the kidney.

Authors’ abstract

Relationships of Sclerostin, a bone anti-anabolic protein, with biomarkers of mineral bone disorders in chronic kidney disease are still unsettled, in particular in kidney transplant (KTR). In 80 KTR patients (31F/49M, 54.7±10.3 years) we studied the relationships of serum Sclerostin with eGFR, Calcium, Phosphate, Alkaline Phosphatase (AP), intact Parathyroid hormone (iPTH), soluble alpha-Klotho (sKlotho), intact Fibroblast Growth Factor 23 (iFGF23), 25-hydroxyvitamin D(25D) and 1,25-dihydroxyvitamin D (1,25D). Thirty healthy subjects (35.0±12.4 years, eGFR 109.1±14.1 ml /min/1,73m2) served as control for Sclerostin, iFGF23 and sKlotho.

With a median eGFR of 46.3 mL/min/1.73m2 (IQR, 36.2 to 58.3) our KTR had median Sclerostin levels of 23.7 pmol/L (IQR: 20.8 to 32.8), not different from controls (26.6 pmol/L, IQR: 22.0 to 32.2; p = n.s). Sclerostin correlated negatively with AP (r =: .251; p = 0.023) and positively with iFGF23 (r = .227; p = 0.017) and 25D (r = .214; p = 0.025). Age-adjusted multiple regression analysis identified AP and 1,25D as negative and 25D and sKlotho as positive best predictors of Sclerostin.

No correlation was evident with eGFR. The negative correlation with AP confirms the direct anti-anabolic role of Sclerostin. The associations either negative or positive with iFGF23, sKlotho, and vitamin D metabolites suggest also a modulatory role in mineral homeostasis. In particular, the associations with iFGF23 (positive) and 1,25D (negative) underline the relevant inhibitory action of Sclerostin on vitamin D activation. In conclusion, Sclerostin levels in KTR are normal and influenced more by bone turnover than by eGFR. Its involvement with other hormones of mineral homeostasis (FGF23/Klotho and Vitamin D) is part of the sophisticated cross-talk between bone and the kidney.

Publication and source details

Original title: Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation

Lida Tartaglione; Marzia Pasquali; Silverio Rotondi; Maria Luisa Muci; Cristiana Leonangeli; Alessio Farcomeni; Valeria Fassino; Sandro Mazzaferro

PLoS ONE · 2017

Competing Interests: The authors have declared that no competing interests exist.

  • Conceptualization: LT MP SM.

  • Data curation: LT SR MLM CL.

  • Formal analysis: AF.

  • Investigation: LT SR MLM CL.

  • Methodology: MP AF SM.

  • Project administration: MP SM.

  • Resources: LT MP SR MLM CL VF.

  • Software: AF.

  • Supervision: SM.

  • Validation: VF.

  • Visualization: LT MP SM.

  • Writing: original draft: LT MP SM.

  • Writing: review & editing: LT MP SM.

* E-mail: sandro.mazzaferro@uniroma1.it
© 2017 Tartaglione et al2017Tartaglione et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.The authors received no specific funding for this work.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T05:32:39.250973+00:00

DOI: 10.1371/journal.pone.0178637 · PMC5448809